A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This study will investigate safety, tolerability and pharmacokinetics of ABT-126 in up to 20
male and female subjects, between 55 to 90 years of age with mild to moderate Alzheimer's
disease on stable doses of acetylcholinesterase inhibitors.